Venetoclax for treating chronic lymphocytic leukaemia - guidance (TA487)

National Institute for Health and Care Excellence - NICE
Publication date:
08 November 2017


Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: The guidance will be updated when the data collection period has ended (expected to be December 2020). Venetoclax will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement